WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315145
CAS#: 120410-24-4
Description: Biapenem (INN) is a carbapenem antibiotic. It has in vitro activity against anaerobes.
MedKoo Cat#: 315145
Name: Biapenem
CAS#: 120410-24-4
Chemical Formula: C15H18N4O4S
Exact Mass: 350.10488
Molecular Weight: 350.39282
Elemental Analysis: C, 51.42; H, 5.18; N, 15.99; O, 18.26; S, 9.15
Synonym: (4R5S6S)3(67dihydro5H pyrazolo12a124triazol8 ium6ylsulfanyl) 6(1hydroxyethyl) 4methyl7oxo1azabicyclo3.2.0hept2 ene2carboxylate
IUPAC/Chemical Name: (4R,5S,6S)-3-((6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
InChi Key: MRMBZHPJVKCOMA-WAOAVRLKSA-N
InChi Code: InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8?,10-,11-/m1/s1
SMILES Code: O=C(C(N12)=C(SC(C3)CN4[N+]3=CN=C4)[C@H](C)[C@]2([H])[C@@H](C(O)C)C1=O)[O-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 350.39282 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Erratum to: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Dec 8. [Epub ahead of print] PubMed PMID: 21140280.
2: Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, Zhang W, Wu G, Zhang G. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010;56(4):285-90. Epub 2010 Aug 11. PubMed PMID: 20714145.
3: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Jul 3. [Epub ahead of print] PubMed PMID: 20602137.
4: Kameda K, Ikawa K, Ikeda K, Morikawa N, Nakashima A, Ohge H, Sueda T. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations. J Chromatogr Sci. 2010 May-Jun;48(5):406-11. PubMed PMID: 20515537.
5: Thamlikitkul V, Trakulsomboon S. In vitro activity of biapenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2010 May;35(5):514. Epub 2010 Feb 25. PubMed PMID: 20188524.
6: Kikuchi E, Kikuchi J, Nasuhara Y, Oizumi S, Ishizaka A, Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother. 2009 Jul;53(7):2799-803. Epub 2009 Apr 20. PubMed PMID: 19380601; PubMed Central PMCID: PMC2704648.
7: Kameda K, Miki M, Ikawa K, Morikawa N, Kobayashi M. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation]. Jpn J Antibiot. 2009 Feb;62(1):1-8. Japanese. PubMed PMID: 19378765.
8: Ikawa K, Morikawa N, Ikeda K, Katagiri M, Kiya K, Isobe N, Mizoue T, Kondo H, Takano M. Pharmacokinetics and pharmacodynamics of biapenem in human cerebrospinal fluid. Int J Antimicrob Agents. 2009 Aug;34(2):184-5. PubMed PMID: 19307107.
9: Xia M, Hang TJ, Zhang F, Li XM, Xu XY. The stability of biapenem and structural identification of impurities in aqueous solution. J Pharm Biomed Anal. 2009 May 1;49(4):937-44. Epub 2009 Feb 13. PubMed PMID: 19278804.
10: Suyama H, Ikawa K, Morikawa N, Ikeda K, Fujiue Y, Morikawa S, Kaneko K, Kuwabara M, Yamanoue T. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Jpn J Antibiot. 2008 Oct;61(5):303-13. PubMed PMID: 19260350.
